Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Nov 4;99(9):1402-7.
doi: 10.1038/sj.bjc.6604732.

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

V Catalano  1 , F Graziano, D Santini, S D'Emidio, A M Baldelli, D Rossi, B Vincenzi, P Giordani, P Alessandroni, E Testa, G Tonini, G Catalano
Affiliations

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

V Catalano et al. Br J Cancer. .

Abstract

No established second-line chemotherapy is available for patients with advanced gastric cancer failing to respond or progressing to first-line chemotherapy. However, 20-40% of these patients commonly receive second-line chemotherapy. We evaluated the influence of clinico-pathologic factors on the survival of 175 advanced gastric cancer patients, who received second-line chemotherapy at three oncology departments. Univariate and multivariate analyses found five factors which were independently associated with poor overall survival: performance status 2 (hazard ratio (HR), 1.79; 95% CI, 1.16-2.77; P=0.008), haemoglobin </=11.5 g l(-1) (HR, 1.48; 95% CI, 1.06-2.05; P=0.019), CEA level >50 ng ml(-1) (HR, 1.86; 95% CI, 1.21-2.88; P=0.004), the presence of greater than or equal to three metastatic sites of disease (HR, 1.72; 95% CI, 1.16-2.53; P=0.006), and time-to-progression under first-line chemotherapy </=6 months (HR, 1.97; 95% CI, 1.39-2.80; P<0.0001). A prognostic index was constructed dividing patients into low- (no risk factor), intermediate- (one to two risk factors), or high- (three to five risk factors) risk groups, and median survival times for each group were 12.7 months, 7.1 months, and 3.3 months, respectively (P<0.001). In the absence of data deriving from randomised trials, this analysis suggests that some easily available clinical factors may help to select patients with advanced gastric cancer who could derive more benefit from second-line chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival curve for the whole group (n=175).
Figure 2
Figure 2
Survival curves according to the risk groups. Marks on survival curves denote censored observations.
See this image and copyright information in PMC

References

    1. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10(Suppl 3): 49–58 - PubMed
    1. Al-Batran S, Hartmann J, Probst S, Hofheinz R, Stoehlmacher H, Schmalenberg H, Hollerbach S, Schuch G, Homann N, Jäger E (2006) A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). J Clin Oncol 24(Suppl 18): LBA4016a
    1. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E (2005) Gastric cancer. Crit Rev Oncol Hematol 54: 209–241 - PubMed
    1. Chau I, Norman AR, Ross PJ, Waters JS, Oates J, Cunningham D (2004a) Multivariate prognostic factor analysis and second-line treatment in locally advanced and metastatic oesophago-gastric cancer – pooled analysis of 1080 patients from three multicentre randomised controlled trials using individual patient data. ASCO Gastrointestinal Cancers Symposium; abstract 5 - PubMed
    1. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004b) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22: 2395–2403 - PubMed